Trial Profile
Camrelizumab (PD-1 Antibody) Compared With Best Supportive Care After Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Randomised Controlled, Phase 3 Trial (DIPPER)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Registrational; Therapeutic Use
- Acronyms DIPPER; PACIFIC-NPC
- 07 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Apr 2022 Planned End Date changed from 1 Feb 2024 to 1 Feb 2026.
- 16 Apr 2022 Planned primary completion date changed from 1 Feb 2022 to 1 Feb 2024.